Study of VTD in Waldenstrom's Macroglobulinemia
Study of VTD in Waldenstrom's Macroglobulinemia
This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the
 efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients
 with newly diagnosed Waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma.
Inclusion Criteria:

 -  Age of 19 or older

 -  Newly diagnosed Waldenstrom's macroglobulinemia or lymphoplasmacytic lymphoma

 -  Previously untreated with chemotherapy

 -  ECOG performance status of 2 or lesser

 -  Peripheral blood white blood cell count ≥ 3,500/uL

 -  Peripheral blood neutrophil count ≥ 1,000/uL

 -  Peripheral blood platelet count ≥ 20,000/uL

 -  Peripheral blood hemoglobin ≥ 6.0g/dL

 -  Serum total bilirubin ≤ 2.0 mg/dL

 -  Serum aspartate aminotransferase ≤ 2.5 x (upper normal limit)

 -  Serum alanine aminotransferase ≤ 2.5 x (upper normal limit)

 Exclusion Criteria:

 -  Diagnosed with other malignancy within 5 years before enrollment

 -  Prior hematopoietic stem cell transplantation

 -  Prior organ transplantation

 -  Uncontrolled central nervous system involvement

 -  Congenital immunodeficiency

 -  Acquired immune deficiency syndrome (AIDS)

 -  Pregnancy

 -  Uncontrolled epilepsy

 -  Uncontrolled psychological disease

 -  Peripheral neuropathy of grade 3 or higher